EVENTIDE ASSET MANAGEMENT, LLC
Q1 2020 13F-HR Holdings
Net value change ($000)
-460,906
(-13.0%)
New positions
24
Sold out positions
18
Turnover %
15.4%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2019
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| CRWD | 54,956 | NEW |
| Karuna Therapeutics, Inc. | 48,692 | 300.8% |
| EXAS | 34,958 | 76.4% |
| DT | 28,631 | 137.2% |
| ROL | 27,936 | NEW |
| KALA | 25,956 | NEW |
| RNG | 25,641 | NEW |
| VRSK | 22,022 | NEW |
| DHI | 21,300 | 1913.7% |
| REGN | 15,088 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| ZOGENIX, INC. | -77,852 | -52.6% |
| Myovant Sciences Ltd. | -57,998 | -90.6% |
| TTD | -52,507 | -47.6% |
| Aimmune Therapeutics, Inc. | -47,690 | -46.2% |
| ASND | -45,031 | -19.1% |
| PANW | -43,113 | -65.0% |
| DNTH | -40,212 | -78.2% |
| Sage Therapeutics, Inc. | -34,341 | -60.2% |
| SRPT | -31,095 | -24.2% |
| IAA, Inc. | -28,707 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
91,960
(3.0% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|